In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, meet in person at the Diabetes Technology Meeting (DTM) in San Francisco to discuss the latest clinical and regulatory advances surrounding semaglutide.

Key Episode Timestamps

00:00:01 Introduction

00:00:42 Oral semaglutide's FDA approval

00:02:02 The SOUL trial and Rybelsus's cardiovascular indication

00:03:35 Dosing for Rybelsus

00:06:18 The SELECT trial

00:08:29 Can GLP-1s be cardiovascular treatments?

00:14:08 Outro